Similar articles

• Use of combination hormone replacement therapy in light of recent data from the Women's Health Initiative.

  Kaunitz AM; Women's Health Initiative. Kaunitz AM, et al. Medscape Womens Health. 2002 Jul-Aug;7(4):8. Medscape Womens Health. 2002. PMID: 12466740 No abstract available.
• [Conjugated estrogen-gestagen does not reduce cardiovascular morbidity. Were these findings (in the Women's Health Initiative study) really unexpected?].

  Henriksson P. Henriksson P. Lakartidningen. 2002 Nov 21;99(47):4716-9. Lakartidningen. 2002. PMID: 12523045 Swedish. No abstract available.
• Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.

  Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators. Prentice RL, et al. Am J Epidemiol. 2006 Apr 1;163(7):589-99. doi: 10.1093/aje/kwj079. Epub 2006 Feb 16. Am J Epidemiol. 2006. PMID: 16484450
• Be careful of what you wish for: putting the WHI Estrogen/Progestin and HERS II Trials in perspective.

  Randolph JF Jr; Women's Health Initiative Estrogen/Progestin and HERS II Trials. Randolph JF Jr, et al. Medscape Womens Health. 2002 Jul-Aug;7(4):7. Medscape Womens Health. 2002. PMID: 12466739 Review. No abstract available.
• New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.

  Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT. Modena MG, et al. Maturitas. 2005 Sep 16;52(1):1-10. doi: 10.1016/j.maturitas.2005.05.003. Maturitas. 2005. PMID: 15963666 Review.